
AbbVie boosts neuroscience portfolio with $8.7 billion acquisition of Cerevel Therapeutics
In a strategic move to fortify its position in the neuroscience drug market, AbbVie announced on Wednesday its plan to acquire Cerevel Therapeutics for a [more…]